[go: up one dir, main page]

PL3749308T3 - Leczenie pacjentów z klasyczną chorobą fabry’ego migalastatem - Google Patents

Leczenie pacjentów z klasyczną chorobą fabry’ego migalastatem

Info

Publication number
PL3749308T3
PL3749308T3 PL19706182.3T PL19706182T PL3749308T3 PL 3749308 T3 PL3749308 T3 PL 3749308T3 PL 19706182 T PL19706182 T PL 19706182T PL 3749308 T3 PL3749308 T3 PL 3749308T3
Authority
PL
Poland
Prior art keywords
migalastat
patients
treatment
fabry disease
classic fabry
Prior art date
Application number
PL19706182.3T
Other languages
English (en)
Inventor
Jay Barth
Elfrida Benjamin
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65494622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3749308(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of PL3749308T3 publication Critical patent/PL3749308T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL19706182.3T 2018-02-06 2019-02-06 Leczenie pacjentów z klasyczną chorobą fabry’ego migalastatem PL3749308T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862626992P 2018-02-06 2018-02-06
PCT/US2019/016853 WO2019157056A1 (en) 2018-02-06 2019-02-06 Treatment of patients with classic fabry disease

Publications (1)

Publication Number Publication Date
PL3749308T3 true PL3749308T3 (pl) 2024-03-25

Family

ID=65494622

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19706182.3T PL3749308T3 (pl) 2018-02-06 2019-02-06 Leczenie pacjentów z klasyczną chorobą fabry’ego migalastatem

Country Status (21)

Country Link
US (1) US20210038579A1 (pl)
EP (2) EP3749308B1 (pl)
JP (2) JP2021512896A (pl)
KR (1) KR20200128675A (pl)
CN (1) CN112203657A (pl)
AR (1) AR114392A1 (pl)
AU (2) AU2019217603A1 (pl)
CA (1) CA3090499A1 (pl)
DK (1) DK3749308T3 (pl)
ES (1) ES2969263T3 (pl)
FI (1) FI3749308T3 (pl)
HR (1) HRP20240025T1 (pl)
HU (1) HUE064761T2 (pl)
LT (1) LT3749308T (pl)
PL (1) PL3749308T3 (pl)
PT (1) PT3749308T (pl)
RS (1) RS65103B1 (pl)
SI (1) SI3749308T1 (pl)
SM (1) SMT202400027T1 (pl)
TW (1) TWI869336B (pl)
WO (1) WO2019157056A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027569T2 (en) 2006-05-16 2016-10-28 Amicus Therapeutics Inc Preparation for the treatment of Fabry disease
CA2715407C (en) 2008-02-12 2022-07-26 Elfrida Benjamin Method to predict response to pharmacological chaperone treatment of diseases
AU2018277756A1 (en) 2017-05-30 2020-01-23 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
EP3749307A1 (en) 2018-02-06 2020-12-16 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
AU2020327019A1 (en) 2019-08-07 2022-03-03 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
HUE027569T2 (en) * 2006-05-16 2016-10-28 Amicus Therapeutics Inc Preparation for the treatment of Fabry disease
AU2008232614A1 (en) 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of Fabry disease using pharmacological chaperones
CA2715407C (en) 2008-02-12 2022-07-26 Elfrida Benjamin Method to predict response to pharmacological chaperone treatment of diseases
WO2017165164A1 (en) * 2016-03-22 2017-09-28 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
TWI875676B (zh) * 2016-07-19 2025-03-11 美商阿米庫斯醫療股份有限公司 治療ert初治的和已經歷ert的患者中之法布瑞氏症
SG11202000423XA (en) * 2017-07-19 2020-02-27 Amicus Therapeutics Inc Treatment of fabry disease in ert-naïve and ert-experienced patients

Also Published As

Publication number Publication date
CA3090499A1 (en) 2019-08-15
HRP20240025T1 (hr) 2024-03-29
US20210038579A1 (en) 2021-02-11
TW201944998A (zh) 2019-12-01
EP4316589A2 (en) 2024-02-07
AU2025200074A1 (en) 2025-01-30
FI3749308T3 (fi) 2024-01-18
DK3749308T3 (da) 2024-01-22
AR114392A1 (es) 2020-09-02
PT3749308T (pt) 2024-01-25
EP3749308A1 (en) 2020-12-16
ES2969263T3 (es) 2024-05-17
SMT202400027T1 (it) 2024-03-13
TWI869336B (zh) 2025-01-11
AU2019217603A1 (en) 2020-09-24
CN112203657A (zh) 2021-01-08
LT3749308T (lt) 2024-02-12
EP4316589A3 (en) 2024-04-24
WO2019157056A8 (en) 2020-12-03
JP2021512896A (ja) 2021-05-20
KR20200128675A (ko) 2020-11-16
WO2019157056A1 (en) 2019-08-15
JP2024026080A (ja) 2024-02-28
HUE064761T2 (hu) 2024-04-28
RS65103B1 (sr) 2024-02-29
SI3749308T1 (sl) 2024-03-29
EP3749308B1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
PL3749308T3 (pl) Leczenie pacjentów z klasyczną chorobą fabry’ego migalastatem
IL276383A (en) Treatment of ophthalmological diseases
IL264301A (en) Treatment of Fabry disease in ert-naive and ert-experienced patients
IL284414A (en) Methods and preparations for the treatment of Fabry disease
IL287904B1 (en) Combined treatment of arthritis
IL269083A (en) Methods for preventing and treating heart disease
PL3268029T3 (pl) Leczenie pacjentów z cukrzycą typu 2
GB201805100D0 (en) Treatment of sarcopenic diseases
SG11202000423XA (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
SG11202010585WA (en) New treatment of interstitial lung diseases
IL254500A0 (en) Treatment of patients with type 2 diabetes
SG11202103972SA (en) Neurological disease treatment with zilucoplan
IL282361A (en) Treatment for neurological diseases
HK40106025A (en) Treatment of patients with classic fabry disease
PL3710043T3 (pl) Fgf10 do leczenia chorób serca
IL263837A (en) Treatment of ocular disease
HK40112175A (en) Treatment of fabry disease in ert-naive and ert-experienced patients
HK40110848A (en) Treatment of fabry disease in ert-naive and ert-experienced patients
HK40109071A (en) Treatment of fabry disease in ert-naive and ert-experienced patients
HK40106068A (en) Treatment of fabry disease in ert-naive and ert-experienced patients
GB201811911D0 (en) Treatment of disease
GB201811912D0 (en) Treatment of disease
GB201810974D0 (en) Treatment of disease
ZA201904327B (en) Treatment of skin conditions
GB201705435D0 (en) Treatment of ocular disease